PCR138 Association of SARS-CoV-2 Omicron Ba.1 on Adherence to Oral Tetrabenazine Congener and Quality of Life of Patients Diagnosed With Huntington's Disease With Chorea or Tardive Dyskinesia on the Service of a USA Specialty Pharmacy

Abstract

During 1/1/-3/31/2022, SARS-CoV-2 Omicron BA.1 (CoVID-19 OBA.1) was pandemic in USA. Two study objectives are to determine if CoVID-19 OBA.1 was associated with a change in: (1) adherence to oral tetrabenazine analogue (TBZa) used to treat Huntington's Disease with chorea (HDc) or Tardive Dyskinesia (TDD) patients serviced by specialty pharmacy's medication therapy management program (SPMTM) and (2) patient-reported quality of life (QOL). A retrospective, observational, pre-/post-design study of HDc,TDD patient adherence to oral TBZa and associated QoL was conducted at beginning of and during CoVID-19 OBA.1 pandemic. Patient assessments (PA) occurred at start of care (SOC) and follow-up (F-U) 7 days before dispenses. PA included EQ-5D-5L QoL metrics. Descriptive statics used to calculate QoL dimensional means before and after starting TDZa and then on F-U SPMTM. Differences in means represented patient perceived changes in QoL. The medication possession ratio (MPR) was calculated using the F-U from both the Pre- and During-CoVID-19 OBA.1. MPR = 0.96 prior to index time and was 0.93 During-CoVID-19 OBA.1 (3.1%). 238 PA were done During-CoVID-19 OBA.1 (280 HDc,TDD patients, 22 SOC, 250 F-U). Differences in QoL means Pre- vs During-CoVID-19 OBA.1 were: Mobility +0.0081 (0.81%), Self-Care +0.002 (0.2%), Usual Activities -0.0022 (0.22%), Pain/Discomfort -0.0103 (1.03%), Anxiety/Depression -0.0089 (0.89%), Overall Health State -0.07 (0.09%). Note: “-” = improvement; ”+”=worsened in Dimensions 1-5; “+” = improvement and ”-“ = worsened in Overall Health state. Percentages = absolute values. MPR decreased by 3.1% compared to Pre-CoVID-19 OBA.1. Pre- and During-CoVID-19 OBA.1 MPR were higher than the industry standard of >0.9.5 On average, patients reported Mobility and Self-Care worsened but improved on Usual Activities, Pain/Discomfort and Anxiety/Depression dimensions of EQ-5D-5L. Over-all Health rating improved slightly by 0.09%. Explanations for worsened QoL metrics are discussed.7 Additional studies are suggested.